fosfomycin and Skin-Diseases--Infectious

fosfomycin has been researched along with Skin-Diseases--Infectious* in 2 studies

Other Studies

2 other study(ies) available for fosfomycin and Skin-Diseases--Infectious

Article	Year
[Combination effects of fosfomycin and other oral antimicrobial agents against methicillin-resistant Staphylococcus aureus]. Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology, 1990, Volume: 100, Issue:12 Combination effects of fosfomycin (FOM) and other oral antimicrobial agents were studied against methicillin-resistant Staphylococcus aureus (MRSA) (methicillin: minimal inhibitory concentration (MIC) greater than or equal to 12.5 micrograms/ml) isolated from skin and skin structure infections. The fractional inhibitory concentration (FIC) index equal to or less than 0.5 was seen in 63.0% of 27 MRSA strains for FOM and minocycline combination, in 44.4% for FOM and cefatrizine, in 44.4% for FOM and cefaclor, in 40.7% for FOM and cefalexin, in 37.0% for FOM and doxycycline, in 29.6% for FOM and erythromycin, in 22.2% for FOM and rokitamycin, in 18.5% for FOM and ofloxacin, in 14.8% for FOM and sultamicillin, in 11.1% for FOM and clavulanic acid/amoxicillin. The combination effects of FOM and minocyclin, or FOM and cephalosporins were higher than other combinations with FOM. Combination of FOM with other antibiotics could be a useful way to treat MRSA skin and skin structure infections. Topics: Administration, Oral; Cephalosporins; Doxycycline; Drug Therapy, Combination; Erythromycin; Fosfomycin; Humans; Methicillin Resistance; Minocycline; Skin; Skin Diseases, Infectious; Staphylococcus aureus	1990
[Use of fosfomycin tablets in the treatment of purulent skin diseases]. The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1 Fourteen patients with purulent skin diseases were treated orally with fosfomycin (FOM) 1.5-3 g in the tablet form for 1 week to determine its efficacy and safety. The results obtained are summarized as follows. 1. The clinical efficacy rate was 71.4%. A bacteriological eradication rate of 71.4% was obtained. 2. As adverse reactions 3 patients experienced diarrhea and abdominal pain. But in all of these patients, symptoms were relieved with a reduction in dosage. 3. Taking the efficacy and the safety into account, utility rate was assessed to be 71.4%. From these results it is considered that FOM tablets are useful equally to conventional FOM capsules. Topics: Adolescent; Adult; Aged; Bacteria; Bacterial Infections; Capsules; Diarrhea; Drug Evaluation; Female; Fosfomycin; Humans; Male; Middle Aged; Pain; Skin Diseases, Infectious; Tablets	1989

Article

Year

[Combination effects of fosfomycin and other oral antimicrobial agents against methicillin-resistant Staphylococcus aureus].

Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology, 1990, Volume: 100, Issue:12

Combination effects of fosfomycin (FOM) and other oral antimicrobial agents were studied against methicillin-resistant Staphylococcus aureus (MRSA) (methicillin: minimal inhibitory concentration (MIC) greater than or equal to 12.5 micrograms/ml) isolated from skin and skin structure infections. The fractional inhibitory concentration (FIC) index equal to or less than 0.5 was seen in 63.0% of 27 MRSA strains for FOM and minocycline combination, in 44.4% for FOM and cefatrizine, in 44.4% for FOM and cefaclor, in 40.7% for FOM and cefalexin, in 37.0% for FOM and doxycycline, in 29.6% for FOM and erythromycin, in 22.2% for FOM and rokitamycin, in 18.5% for FOM and ofloxacin, in 14.8% for FOM and sultamicillin, in 11.1% for FOM and clavulanic acid/amoxicillin. The combination effects of FOM and minocyclin, or FOM and cephalosporins were higher than other combinations with FOM. Combination of FOM with other antibiotics could be a useful way to treat MRSA skin and skin structure infections.

Topics: Administration, Oral; Cephalosporins; Doxycycline; Drug Therapy, Combination; Erythromycin; Fosfomycin; Humans; Methicillin Resistance; Minocycline; Skin; Skin Diseases, Infectious; Staphylococcus aureus

1990

[Use of fosfomycin tablets in the treatment of purulent skin diseases].

The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1

Fourteen patients with purulent skin diseases were treated orally with fosfomycin (FOM) 1.5-3 g in the tablet form for 1 week to determine its efficacy and safety. The results obtained are summarized as follows. 1. The clinical efficacy rate was 71.4%. A bacteriological eradication rate of 71.4% was obtained. 2. As adverse reactions 3 patients experienced diarrhea and abdominal pain. But in all of these patients, symptoms were relieved with a reduction in dosage. 3. Taking the efficacy and the safety into account, utility rate was assessed to be 71.4%. From these results it is considered that FOM tablets are useful equally to conventional FOM capsules.

Topics: Adolescent; Adult; Aged; Bacteria; Bacterial Infections; Capsules; Diarrhea; Drug Evaluation; Female; Fosfomycin; Humans; Male; Middle Aged; Pain; Skin Diseases, Infectious; Tablets

1989